Market Intelligence for Copper Metabolism Modulation, Menkes Disease Gene Therapy, Platinum Resistance, and Cuproptosis Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP7A drug discovery. The table below integrates all key components from multiple validated sources, covering antigens, gene delivery vectors, antibodies, siRNA, and related targets for comprehensive pathway analysis.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP7A Recombinant Soluble Domain / Intracellular Domain (ICD) / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for ELISA, SPR, and enzymatic assays. |
View ATP7A Products |
| Gene Delivery | ATP7A Lentivirus Premade Particles (Full-length ORF) Essential for stable cell line construction (HEK293/CHO). Preserves native 8-transmembrane conformation for copper/platinum efflux assays. |
View ATP7A Products |
| Benchmark Ab | Anti-ATP7A (Reference Sequence, Biosimilar) Recombinant positive control for Western blot, flow cytometry, and immunohistochemistry. Sequence Verified. |
View ATP7A Products |
| Validator | ATP7A siRNA Set (3 Unique Sequences) For knockdown verification and specificity controls in transport/viability assays. |
View ATP7A Products |
| Related Target | ATP7B (Wilson Disease Protein) Paralogous copper ATPase for selectivity counter-screening and systemic copper homeostasis analysis. |
View ATP7B Products |
| Related Target | SLC31A1 (CTR1) Copper importer; synergistic pathway node for combination therapy and platinum resistance studies. |
View SLC31A1 Products |
| Related Target | ATOX1 Cytoplasmic copper chaperone interacting with ATP7A metal-binding domains; upstream regulator of copper delivery. |
View ATOX1 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex 8-Transmembrane Topology & Functional Transport | Lentivirus-mediated Stable Cell Lines (HEK293/CHO) preserving native membrane conformation for transport assays |
| Subcellular Trafficking (Golgi to Plasma Membrane) | Sequence Verified ORF with N-terminal/C-terminal fluorescent tags (GFP/mCherry) for live-cell imaging |
| Paralog Selectivity (ATP7A vs ATP7B) | Human/Mouse/Cyno ATP7A and ATP7B ortholog proteins and cell pairs available; MS/sequencing verified |
| Menkes Disease Variant Modeling | Custom Mutation Service (Gly709Arg, Thr977Met, etc.) in lentiviral backbone |
| False Positives & Specificity Controls | Validated siRNA sets, benchmark antibodies, and endotoxin-controlled proteins included |
| Lack of Functional Assay Standards | Clinical Benchmark Antibodies (Biosimilar sequences) for assay standardization |
Live ATP7A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Menkes Disease Clinical Trials
- View ATP7A Oncology & Resistance Research
- View ATP7A Gene Therapy Developments
- View Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ATP7A therapeutics spans rare disease and oncology. In Menkes disease, first-generation copper-histidine supplementation remains standard of care, while next-generation gene therapy vectors (AAV/lentiviral) aim to correct the underlying copper transport defect. Concurrently, oncology pipelines are increasingly interrogating ATP7A as a biomarker and resistance mechanism in platinum-based chemotherapy, and as a key node in cuproptosis (copper-dependent cell death). As the field advances, the demand for physiologically relevant cell-based transport assays, stringent paralog selectivity screening (ATP7A vs ATP7B), and recombinant proteins for biochemical screening is becoming the primary technical bottleneck.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy | Cyprium Therapeutics (Aceragen), Passage Bio, Academic Consortia | Menkes Disease | Functional Complementation Assays (Need high-titer Lentivirus for transduction efficiency modeling and rescue validation) |
| Small Molecule Chaperones | Academic Rare Disease Foundations | Menkes Disease (mild variants) | Membrane Trafficking Rescue Assays (Need fluorescent-tagged Lentivirus for Golgi/plasma membrane quantification) |
| Small Molecule Inhibitors | Preclinical Biotech / Academia | Platinum-Resistant Solid Tumors (ovarian, NSCLC) | Selectivity Assay (Need High-Purity ATP7A vs ATP7B ICDs for enzymatic screening; Cell-based efflux assays) |
| Copper Ionophores / Chelators | Therapontos, Exo Therapeutics, Oncology Consortia | Cuproptosis-targeted Cancers | Target Knockdown Validation (Need Validated siRNA sets to confirm mechanism; Cell viability in combination with elesclomol) |
| Antisense Oligonucleotides / RNA-based | Biogen, Ionis (pipeline) | Menkes Disease / Wilson Spectrum | Knockdown Validation (Need validated siRNA controls for specificity) |
Note: All products and services are backed by sequence verification, quality control (endotoxin <1EU/ug for proteins, >10^8 TU/mL for lentivirus), and custom mutation capabilities for Menkes disease variant modeling.